

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 13, line 2 as follows:

wherein RL1, RL2, and RL3 ~~and RL6~~ are independently selected from Lys, Arg or Orn; RL4 and RL6 ~~are~~ is independently selected from Asp or Glu; and RL5 is independently selected from Ser, Thr, Asp, or Glu, wherein said structure is linear or cyclic.

Please amend the paragraph beginning on page 13, line 14 as follows:

According to the invention, the structure of formula (VII) may be a peptide sequence selected from the peptide sequence from Arg124 to ~~Ser171~~ Asp171 in the ID No.1 sequence shown in Fig. 6a, the peptide sequence from Arg25 to Glu72 in the ID No.2 sequence shown in Fig. 6b, the peptide sequence from Lys100 to Glu147 in the ID No.3 sequence shown in Fig. 6c, the sequence from Arg24 to Glu71 in the ID No.4 sequence shown in Fig. 6d, the sequence from Arg97 to Asp144 in ID No.5 sequence shown in Fig. 6d, or a modified sequence of these sequences provided that RL1, RL2, and RL3 ~~and RL6~~ are independently selected from Lys, Arg, or Orn;

Please amend the paragraph beginning on page 13, line 26 as follows:

RL4 and RL6 is independently selected from Asp or Glu, and RL5 is independently selected from Ser, Thr, Asp or Glu.

Please amend the paragraph beginning on page 14, line 14 as follows:

wherein RL1 ~~and RL6~~ are independently selected from Lys, Orn and Arg; RL2 and RL3 are Arg; RL4, RL5, and RL6 ~~and RL5~~ are independently selected from Asp and Glu;

Please amend the paragraph beginning on page 30, line 15 as follows:

a) it includes in particular at least 6 residues, so-called residual ligands, named RL1-RL6 and their nature is the following:

RL1 = Arg or Lys or Orn

RL2 = Arg or Lys or Orn

RL3 = Arg or Lys or Orn

RL4 = Asp or Glu

RL5 = Ser or Thr or Asp or Glu

RL6 = ~~Arg or Lys or Orn~~ Asp or Glu